Akorn, Inc. (AKRX) Reports Mixed Q2 Results
More News related to AKRX
- Unusual 11 Mid-Day Movers 12/31: DDSS, GILT, PNX, CWST Higher; NFLD, RTIX, PAY, LZB Lower
- Morning Movers 12/31: Puget Energy (PSD) Up After Buyout Gets Okay; VeriFone (PAY) Lower On 10-K Delay
- Akorn (AKRX) JV Announces FDA Approval For Sterile Vancomycin HCl USP
- Akorn-Strides, LLC Announces FDA Approvals for Sterile Vancomycin HCl USP, 500 mg/Vial; 1 g/Vial and Sterile Vancomycin HCl USP, 5 g/Vial Pharmacy Bulk Package
- Akorn (AKRX) Responds to FDA Draft Guidance for Industry on Bioequivalence Recommendation for Vancomycin HCl
Akorn, Inc. (Nasdaq: AKRX) reports Q2 loss of $0.03, 1 cent better than the analyst estimate of ($0.04). Revenues for the quarter were $21.2 million, versus the consensus of $18.50 million.
Related Categories
EarningsStocks Mentioned
+0.11Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
